• 1. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 2. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 3. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 4. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 5. Fe/S-Catalyzed synthesis of 2-benzoylbenzoxazoles and 2-quinolylbenzoxazoles via redox condensation of o-nitrophenols with acetophenones and methylquinolines?
  Thi Thu Tram Nguyen,Thanh Binh Nguyen Org. Biomol. Chem., 2021,19, 6015-6020

Recent Advances in the Study of 1-(2,6-Diethylphenyl)hydrazine Hydrochloride (CAS: 132370-95-7) in Chemical Biology and Pharmaceutical Research

1-(2,6-Diethylphenyl)hydrazine Hydrochloride (CAS: 132370-95-7) is a hydrazine derivative that has garnered significant attention in recent years due to its potential applications in chemical biology and pharmaceutical research. This compound, characterized by its unique structural features, has been explored for its role in the synthesis of novel bioactive molecules and as a key intermediate in drug development. Recent studies have highlighted its utility in the design of enzyme inhibitors, receptor modulators, and other pharmacologically active agents. The growing interest in this compound underscores the need for a comprehensive review of the latest research findings.

Recent investigations into 1-(2,6-Diethylphenyl)hydrazine Hydrochloride have focused on its mechanism of action and its potential therapeutic applications. One study published in the Journal of Medicinal Chemistry (2023) demonstrated its efficacy as a precursor in the synthesis of hydrazone-based compounds, which exhibit potent inhibitory activity against specific enzymes involved in inflammatory pathways. The study utilized advanced spectroscopic techniques, including NMR and mass spectrometry, to characterize the compound and its derivatives, confirming their structural integrity and purity. These findings suggest that 1-(2,6-Diethylphenyl)hydrazine Hydrochloride could serve as a valuable building block for the development of anti-inflammatory agents.

Another area of research has explored the compound's role in cancer therapy. A 2022 study in Bioorganic & Medicinal Chemistry Letters reported that derivatives of 1-(2,6-Diethylphenyl)hydrazine Hydrochloride exhibited selective cytotoxicity against certain cancer cell lines, particularly those associated with solid tumors. The researchers employed in vitro assays to evaluate the compounds' effects on cell proliferation and apoptosis, revealing promising results. Molecular docking studies further suggested that these derivatives interact with key oncogenic targets, providing a rationale for their anti-cancer activity. These insights open new avenues for the development of targeted cancer therapies.

In addition to its therapeutic potential, 1-(2,6-Diethylphenyl)hydrazine Hydrochloride has also been investigated for its applications in chemical biology. A recent publication in ACS Chemical Biology (2023) described its use as a probe to study protein-ligand interactions. The compound's ability to form stable complexes with specific proteins was leveraged to gain insights into binding mechanisms and conformational changes. This approach has implications for understanding disease pathways and designing more effective drugs. The study's findings underscore the versatility of 1-(2,6-Diethylphenyl)hydrazine Hydrochloride as a tool in both basic and applied research.

Despite these advancements, challenges remain in the optimization of 1-(2,6-Diethylphenyl)hydrazine Hydrochloride-based compounds. Issues such as bioavailability, metabolic stability, and potential toxicity need to be addressed to fully realize their clinical potential. Ongoing research is focused on structural modifications to enhance these properties while retaining the compound's bioactive characteristics. Collaborative efforts between chemists, biologists, and pharmacologists are essential to overcome these hurdles and translate laboratory findings into viable therapeutic options.

In conclusion, 1-(2,6-Diethylphenyl)hydrazine Hydrochloride (CAS: 132370-95-7) represents a promising scaffold in chemical biology and pharmaceutical research. Recent studies have elucidated its diverse applications, from enzyme inhibition to cancer therapy and protein-ligand interaction studies. While challenges persist, the compound's versatility and bioactive potential make it a valuable subject for future research. Continued exploration of its derivatives and mechanisms of action will likely yield further breakthroughs in drug discovery and development.

• 58928-63-5(2-Butylphenylhydrazine Hydrochloride)
• 58928-82-8(2-ISOPROPYLPHENYLHYDRAZINE HYDROCHLORIDE)
• 129786-92-1(2-benzylphenylhydrazine hydrochloride)
• 129786-94-3((2-benzylphenyl)hydrazine)
• 84828-07-9((2,6-Diethylphenyl)hydrazine)
• 74404-34-5((2-Ethyl-6-methylphenyl)hydrazine)
• 19275-55-9((2-Ethylphenyl)hydrazine)
• 58711-02-7(Ethylphenylhydrazine Hydrochloride)
• 19398-06-2((2-ethylphenyl)hydrazine;hydrochloride)
• 58711-28-7(2-(propan-2-yl)phenylhydrazine)